NEUROTOXICOLOGY.
NEUROTOXICITY.
Brain Organoid-on-chip.
NETRI has successfully demonstrated that cerebral organoids grow more consistently in NETRI's 3D platforms, providing a more reliable starting point for toxicity testing.
Using H2O2 as a proof of concept, NETRI has also developed decision tree algorithms to perform noninvasive quality control during culture and explore the impact of toxins, enhancing our ability to predict neurotoxic effects in a controlled, repeatable manner.
• Biphenyl quantification and effect on brain organoid.
• Vanilin quantification and effect on brain organoid.
TOXICOLOGY.
Liver 3D cell culture matrix.
NETRI recently announced the acquisition of HCS Pharma's assets and BioMIMESYS® products. BIOMIMESYS® is a breakthrough 3D cell culture matrix, mimicking in vivo conditions to recreate functional organs in vitro, enhancing predictivity.
• Long-term, functional 3D hepatocyte cultures.
• Improving liver toxicity prediction by mimicking the in vivo microenvironment in static and dynamic systems.
INNERVATED GUT.
Neuroactive compound testing.
NETRI's neuronal wetware acts as a biodigital sensor, reliably detecting gut-relevant inflammatory (LPS) and neuroprotective (propionate) signals through measurable changes in electrophysiological activity—demonstrating its potential for gut-brain studies.
• Propionate (PA) has shown neuroprotective effects (observed inhibition of the electrical activity).
• LPS has shown neuromodulatory effects (observed increased electrical activity).
OTHER POSSIBILITIES.
Next Applications & Models.
NETRI's patented technologies make it possible to innervate any organ, using electrophysiological recordings as a unique readout.
• Co-culture of hiPSC-derived sensory neurons, gut cells & microbiota (innervated and vascularized skin platform).
• Innervated 3D gut organoid.
• Specific organs ECM (liver, skin, brain, oncology) with BioMIMESYS®.
THE WAY WE WORK.
Out-Licensing.
• Co-development to set up new model & digital library.
• Technology transfert to integrate our technologies in your routine drug development.
• Out-licensing to feed your digital library with new signatures.
Organs-on-chip devices.
• Ready-to-use organs on chip devices.
• 2D and 3D cell culture.
• Innervation & vascularization.
• Classic readouts (sequencing, dosing, imaging...).
• Electrophysiology readouts (MEA).
